A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Metastatic or Recurrent Breast Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2011
At a glance
- Drugs Docetaxel; SGN-15
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 21 Oct 2011 Actual end date (Apr 2003) added as reported by ClinicalTrials.gov.
- 13 Jul 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Jun 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.